Galderma Targets Menopause Skin Care Gap with Clinical Trial Inclusivity Push
Event summary
- Galderma presented global survey findings at IMCAS 2026, revealing over 50% of menopausal women learned about skin changes through personal experience.
- The company will now include menopausal status in clinical trials to better understand treatment efficacy for this demographic.
- Survey of 4,300+ peri- and post-menopausal women across nine countries showed aesthetic treatments had the highest satisfaction rates for addressing skin changes.
- Galderma's portfolio includes Sculptra® biostimulators and Restylane® hyaluronic acid treatments designed to address menopause-related skin degradation.
The big picture
Galderma's initiative addresses a significant knowledge gap in menopause-related skin care, positioning the company to lead in this emerging segment of aesthetic medicine. The move aligns with broader industry trends toward personalized dermatological solutions and inclusive clinical research practices. With 85% of aesthetic patients being female, understanding menopausal skin changes represents both a market opportunity and a patient need.
What we're watching
- Market Expansion Potential
- Whether Galderma can capitalize on the underserved menopause skin care market through targeted product development and clinical insights.
- Competitive Positioning
- How this strategic focus will differentiate Galderma from competitors in the aesthetic dermatology space.
- Regulatory Adaptation
- The pace at which other dermatology players adopt similar clinical trial inclusivity standards for menopausal patients.
Our editorial coverage: